Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Patient demographics^{^a}
Total Completely Recovered Incompletely Recovered P Value
No. of patients 20 11 9 NA
Sex (female/total) 5/20 2/11 3/9 .62
Age (yr) 48 (36–55) 44 (35–48) 55 (51–63) .028
Time since the completion of RT (yr) 10.5 (5–20) 12 (7–20) 8 (5–14) .62
Period of follow-up (mo) 8.5 (1–18) 1 (1–2) 18 (10–22) .002
Surgical resection 15/20 8/11 7/9 1
Concurrent chemotherapy at the first diagnosis 16/20 9/11 7/9 1
Episode of migraine at the diagnosis 12/20 8/11 4/9 .36
Steroid treatment 11/20 3/11 8/9 .01
Antiepileptic or antimigraine drugs 12/20 7/11 5/9 1
Antiangiogenic drug 1/20 1/11 0/9 1
Recurrent episode of SMART syndrome 11/20 6/11 5/9 1
Note:—RT indicates radiation therapy; NA, not applicable.
↵a Values were described as median (interquartile range).

	Total	Completely Recovered	Incompletely Recovered	P Value
No. of patients	20	11	9	NA
Sex (female/total)	5/20	2/11	3/9	.62
Age (yr)	48 (36–55)	44 (35–48)	55 (51–63)	.028
Time since the completion of RT (yr)	10.5 (5–20)	12 (7–20)	8 (5–14)	.62
Period of follow-up (mo)	8.5 (1–18)	1 (1–2)	18 (10–22)	.002
Surgical resection	15/20	8/11	7/9	1
Concurrent chemotherapy at the first diagnosis	16/20	9/11	7/9	1
Episode of migraine at the diagnosis	12/20	8/11	4/9	.36
Steroid treatment	11/20	3/11	8/9	.01
Antiepileptic or antimigraine drugs	12/20	7/11	5/9	1
Antiangiogenic drug	1/20	1/11	0/9	1
Recurrent episode of SMART syndrome	11/20	6/11	5/9	1